Coeptis Therapeutics Holdings (COEP) - Updating Company Profile

Hello,

My firm works with Coeptis Therapeutics Holding (COEP) to manage its investor relations. What’s the best way to update outdated information on the following page: https://seekingalpha.com/symbol/COEP?

In particular, the description and website are inaccurate and should be updated with the content below.

Please advise on the best process.

Thanks

Website: https://coeptistx.com/

Description:

Coeptis Therapeutics Holdings, Inc., together with its subsidiaries including Coeptis Therapeutics, Inc. and Coeptis Pharmaceuticals, Inc., (collectively “Coeptis”), is a biopharmaceutical company developing innovative cell therapy platforms for cancer that have the potential to disrupt conventional treatment paradigms and improve patient outcomes. Coeptis' product portfolio and rights are highlighted by a universal, multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), and a cell therapy technology (CD38-GEAR-NK) and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which Coeptis is developing with VyGen-Bio and leading medical researchers at the Karolinska Institutet. Coeptis' business model is designed around maximizing the value of its current product portfolio and rights through in-license agreements, out-license agreements and co-development relationships, as well as entering into strategic partnerships to expand its product rights and offerings, specifically those targeting cancer. Coeptis was founded in 2017 and is headquartered in Wexford, PA. For more information on Coeptis visit https://coeptistx.com/.